Welichem is seeking partnership to further develop WBI-5111 globally in the area of solid
WBI-5111 is a first-in-class small molecule anticancer drug candidate targeting carbonic
anhydrase IX (CAIX) and currently under evaluating for the maximal tolerable dose in a phase I
clinical study on late stage patients with solid cancers. Results are expected during the first half
of year 2016.
Contact: Dr. Michael Lyle, PhD, VP, R&D; email@example.com